Safety and Efficacy Study of A Novel Ointment to Treat Plaque Type Psoriasis

• ClinicalTrials.gov Identifier: NCT00759161
• Recruitment Status: Completed
• First Posted: September 25, 2008
• Results First Posted: March 6, 2017
• Last Update Posted: March 6, 2017
• Sponsor: Pfizer
• Information provided by (Responsible Party): Pfizer

Study Description

Brief Summary:

The purpose of the study is to determine the safety and efficacy of AN2728 Ointment, 5%, compared to Ointment Vehicle in the treatment of plaque type psoriasis.

Condition or disease	Intervention/treatment	Phase
Psoriasis	Drug: AN2728; Drug: AN2728 Ointment Vehicle	Phase 2

Detailed Description:

This is a multi-center, randomized, double-blind bilateral design. Patients will apply the test articles, AN2728 Ointment, 5%, and Ointment Vehicle twice daily. The assigned study medication will be applied to two comparable treatment targeted plaques identified at baseline. One test article will be applied to one plaque and the other test article to an anatomically distinct plaque. All efficacy evaluations will be measured from only the two plaques identified at the baseline visit.

Study Design

• Study Type: Interventional (Clinical Trial)
• Actual Enrollment: 35 participants
• Allocation: Randomized
• Intervention Model: Parallel Assignment
• Masking: Triple (Participant, Investigator, Outcomes Assessor)
• Primary Purpose: Treatment
• Official Title: A Double-Blind, Randomized Bilateral Study of the Safety and Efficacy of AN2728 Ointment, 5%, Versus Ointment Vehicle in the Treatment of Patients With Plaque Type Psoriasis
• Study Start Date: November 2007
• Actual Primary Completion Date: March 2008
• Actual Study Completion Date: March 2008

Arms and Interventions

Arm	Intervention/treatment
Active Comparator: 1; AN2728 Ointment, 5%	Drug: AN2728; AN2728 Ointment, 5%, twice daily for 4 weeks; Other Name: AN2728 Ointment, 5%
Placebo Comparator: 2; AN2728 Ointment Vehicle	Drug: AN2728 Ointment Vehicle; AN2728 Ointment Vehicle, twice daily for 4 weeks.

Outcome Measures

Primary Outcome Measures :

1. Percentage of Participants With Greater Decrease in Overall Target Plaque Severity Score (OTPSS) at Day 28 [ Time Frame: Day 28 ]
   OTPSS is a scale to assess plaque severity. Each target plaque was scored on a severity rating scale ranging from 0 (no plaque) to 8 (very severe plaque), where higher score indicated more severity of a plaque. In this outcome measure, percentage of participants with reduced OTPSS at Day 28 were reported and comparison of ointment and vehicle treated plaque was given as 'Ointment treated plaque versus (vs.) vehicle treated plaque' and 'Vehicle treated plaque vs. ointment treated plaque'.

Secondary Outcome Measures :

1. Change From Baseline in Overall Target Plaque Severity Score (OTPSS) at Day 7,14, 21, 28 and 35 [ Time Frame: Baseline (Day 1), Day 7,14, 21, 28, 35 ]
   OTPSS is a scale to assess plaque severity. Each target plaque was scored on a severity scale ranging from 0 (no plaque) to 8 (very severe plaque), where higher score indicated more severity of a plaque.
2. Change From Baseline in Erythema at Day 7,14, 21, 28 and 35 [ Time Frame: Baseline (Day 1), Day 7,14, 21, 28, 35 ]
   Erythema is used to assess plaque severity. Investigator rated the clinical appearance of erythema on a severity scale, ranging from 0 (no color on plaque, no erythema) to 8 (extreme red color on plaque, severe erythema), where higher score indicated more severe condition.
3. Change From Baseline in Scaling at Day 7,14, 21, 28 and 35 [ Time Frame: Baseline (Day 1), Day 7,14, 21, 28, 35 ]
   Scaling is a scale to assess plaque severity. Investigator rated the clinical appearance of scaling on a severity scale, ranging from 0 (no scaling on plaque) to 8 (very thick scales on plaque), where higher score indicated more severe condition.
4. Change From Baseline in Plaque Elevation at Day 7,14, 21, 28 and 35 [ Time Frame: Baseline (Day 1), Day 7,14, 21, 28, 35 ]
   Plaque elevation is a scale to assess plaque severity. Investigator rated presence of plaque elevation on a severity scale ranging, from 0 (no plaque elevation) to 8 (very marked plaque elevation), where higher score indicated more severe condition.
5. Percentage of Participants With Greater Decrease in Overall Target Plaque Severity Score (OTPSS) at Day 7,14, 21 and 35 [ Time Frame: Day 7,14, 21, 35 ]
   OTPSS is a scale to assess plaque severity. Each target plaque was scored on a severity rating scale ranging from 0 (no plaque) to 8 (very severe plaque), where higher score indicated more severity of a plaque. In this outcome measure, percentage of participants with reduced OTPSS at Day 7, 14, 21 and 35 were reported and comparison of ointment and vehicle treated plaque was given as 'Ointment treated plaque vs. vehicle treated plaque' and 'Vehicle treated plaque vs. ointment treated plaque'.

Eligibility Criteria

• Ages Eligible for Study: 18 Years and older (Adult, Older Adult)
• Sexes Eligible for Study: All
• Accepts Healthy Volunteers: No

Criteria

Inclusion Criteria:

1. Male or female >18 years of age at time of enrollment.
2. The clinical diagnosis of stable plaque psoriasis.

3. Two target plaques of similar severity

   1. ≥ 5 cm2 but ≤ 100 cm2 computed by multiplying the greatest diameter of the plaque by the diameter of the plaque perpendicular to the greatest diameter.
   2. Bilaterally located (right/left) plaques on the arms or plaques located on the upper and lower trunk. Plaques located on the trunk were to be separated by at least 10 cm and designated by the Investigator as either left/right or front/back.
   3. Target plaque severity score of 2-4 (mild to moderate).
4. Normal or not clinically significant screening laboratory results.
5. Subjects who were willing and able to apply study drug as directed, comply with study instructions, and commit to all follow-up visits.
6. Subjects who had the ability to understand, agree to and sign the study Informed Consent Form (ICF) prior to initiation of any protocol related procedures.

Exclusion Criteria:

1. Any dermatological conditions that could interfere with clinical evaluations or any disease state or physical condition which might expose the patient to an unacceptable risk by study participation
2. Any underlying disease(s) or other dermatological conditions that require the use of exclusionary topical or systemic therapy (see below)
3. Known sensitivity to any of the components of the study medication
4. Spontaneously improving or rapidly deteriorating psoriatic plaques or pustular/exfoliative, guttate, erythrodermic or other non-plaque form of psoriasis
5. Concomitant use of topical or systemic therapies that might alter the course of psoriasis
6. Females of child bearing potential. Females must be post-menopausal (based on FSH levels) or surgically sterile (oophorectomy)

7. Washout periods of:

   1. Topical drugs that might alter the course of psoriasis: 2 weeks
   2. Oral retinoids: 8 weeks
   3. Non-retinoid systemic drugs that might alter the course of psoriasis: 4 weeks
   4. PUVA: 4 weeks
   5. UVB therapy: 4 weeks
   6. Use of emollients/moisturizers on area(s) to be treated: 2 days prior to baseline visit
8. AIDS or AIDS related illness
9. Concurrent participation in another drug research study or within 30 days of enrollment
10. Use of lithium or hydroxychloroquine containing products (i.e. Plaquenil)
11. Use of a beta-blocking medication (i.e. propranolol) if the dose has not been stabilized for at least 3 months

Contacts and Locations

Locations

Mexico

IMIC

Mexico City, Distrito Federal, Mexico, 06700

Sponsors and Collaborators

Pfizer

Investigators

• Study Director: Pfizer CT.gov Call Center; Pfizer

More Information

• Responsible Party: Pfizer
• ClinicalTrials.gov Identifier: NCT00759161
• Other Study ID Numbers: AN2728-PSR-201; C3291014 ( Other Identifier: Pfizer )
• First Posted: September 25, 2008
• Results First Posted: March 6, 2017
• Last Update Posted: March 6, 2017
• Last Verified: January 2017

Keywords provided by Pfizer:

Plaque Type Psoriasis; Topical

Additional relevant MeSH terms:

Psoriasis; Skin Diseases, Papulosquamous; Skin Diseases